Veracyte (VCYT) Common Equity (2012 - 2026)

Veracyte has reported Common Equity for 15 years, with the latest figure at $1.4 billion in Q2 2026.

• Common Equity for Q2 2026 came in at $1.4 billion, up 13.71% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 13.71% YoY), and the FY2025 annual result was $1.3 billion, up 11.36% from the prior year.
• Common Equity climbed to $1.4 billion in Q2 2026, from $1.3 billion in the prior quarter.
• Over five years, Common Equity peaked at $1.4 billion in Q2 2026 and troughed at $1.0 billion in Q4 2023.
• A 5-year average of $1.2 billion and a median of $1.1 billion in 2024 frame the typical range for Common Equity.
• The widest annual swing landed in 2022, when Common Equity retreated 5.32%; it then climbed 13.71% in 2026.
• A 5-year view of Common Equity shows it stood at $1.1 billion in 2022, then slipped by 2.89% to $1.0 billion in 2023, then rose by 12.63% to $1.2 billion in 2024, then climbed by 11.36% to $1.3 billion in 2025, then advanced by 6.02% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.4 billion in Q2 2026, $1.3 billion in Q1 2026, and $1.3 billion in Q4 2025.